Value of T2WI signal intensity and gadobemeglumine enhanced MRI hepatobiliary phase parameters in evaluating liver function of cirrhosis patients

doi:10.3969/j.issn.1004-583X.2025.03.010

Abstract

Abstract:

Objective To investigate the correlation of T2-weighted imaging (T₂WI) signal intensity and gadobenate dimeglumine (Gd-BOPTA) hepatobiliary phase (HBP) parameters with liver function grade, and to analyze their value in the diagnosis of liver function alone and combination. Methods A total of 57 cirrhosis patients who underwent enhanced magnetic resonance imaging (MRI) on T₂WI and Gd-BOPTA from June 2019 to September 2024 were retrospectively collected. At the hilar level, the region of interest (ROI) with the same size was placed on the left, right anterior and right posterior lobes of the liver on T₂WI, plain scan and 90-min MRI images of the hepatobiliary phase. The signal intensity of T₂WI (SI_T2), T₁WI (SIplain scan) and hepatobiliary phase (SI_HBP) were measured, and relative enhancement (RE) was calculated. The parameters in cirrhosis patients possessing different Child-Pugh grades were compared. The correlation between the parameters and Child-Pugh grades was discussed. The diagnostic efficacy of Child-Pugh grade B+C was analyzed, and the difference between the diagnostic efficacy was compared. Results There were significant differences in SI_T2, SI_HBP and RE among cirrhosis patients with different Child-Pugh grades (P<0.05). SI_T2 was positively correlated with Child-Pugh classification (r=0.408, P=0.002). SI_HBP and RE were negatively correlated with Child-Pugh grade (r=-0.365,-0.376, P=0.005, 0.004). However, there was no correlation between SI plain scan and the Child-Pugh grade (P=0.753). The area under the curve (AUC) of SI_T2, SI_HBP, RE and their combination in diagnosing Child-Pugh B+C cirrhosis was 0.715, 0.707, 0.757 and 0.846, respectively. The AUC of SI_T2+SI_HBP +RE was significantly larger than that of SI_HBP (P<0.05). Conclusion SI_T2, Gd-BOPTA HBP parameters SI_HBP and RE are related to liver function grading in cirrhosis patients. Each possess a certain value in diagnosing liver function grading, and their combination reaches a higher efficiency.

Key words: liver cirrhosis, T₂WI, gadobenate dimeglumine, hepatobiliary phase, liver function

CLC Number:

R575.2

Lin Tao, Du Taoming, Li Ya, Feng Yuling, Song Huizhen, Yu Qin. Value of T₂WI signal intensity and gadobemeglumine enhanced MRI hepatobiliary phase parameters in evaluating liver function of cirrhosis patients[J]. Clinical Focus, 2025, 40(3): 251-256.

Add to citation manager EndNote|Ris|BibTeX

URL: http://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2025.03.010

http://www.lchc.cn/EN/Y2025/V40/I3/251

Figures/Tables 8

References 20

[1]	Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world[J]. J Hepatol, 2019, 70(1): 151-171. doi: S0168-8278(18)32388-2 pmid: 30266282
[2]	Ginès P, Krag A, Abraldes JG, et al. Liver cirrhosis[J]. Lancet, 2021, 398(10308):1359-1376.
[3]	Haimerl M, Verloh N, Zeman F, et al. Gd-EOB-DTPA-enhanced MRI for evaluation of liver function: Comparison between signal-intensity-based indices and T1 relaxometry[J]. Sci Rep, 2017, 7:43347. doi: 10.1038/srep43347 pmid: 28266528
[4]	Yip TC, Lyu F, Lin H, et al. Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: Present and future[J]. Clin Mol Hepatol, 2023, 29(Suppl):S171-S183.
[5]	Tang A. Liver stiffness at MR elastography: A surrogate biomarker for staging liver fibrosis, predicting clinical outcomes, and selecting patients[J]. Radiology, 2024, 311(2):e240890.
[6]	Wells ML, Fenstad ER, Poterucha JT, et al. Imaging findings of congestive hepatopathy[J]. Radiographics, 2016, 36(4):1024-1037. doi: 10.1148/rg.2016150207 pmid: 27284758
[7]	Noone TC, Semelka RC, Siegelman ES, et al. Budd-chiari syndrome:Spectrum of appearances of acute,subacute,and chronic disease with magnetic resonance imaging[J]. J Magn Reson Imaging, 2000, 11(1):44-50. doi: 10.1002/(sici)1522-2586(200001)11:1<44::aid-jmri6>3.0.co;2-o pmid: 10676619
[8]	Dahlqvist Leinhard O, Dahlström N, Kihlberg J, et al. Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: A pilot study[J]. Eur Radiol, 2012, 22(3): 642-653. doi: 10.1007/s00330-011-2302-4 pmid: 21984449
[9]	Pastor CM, Wissmeyer M, Millet P. Concentrations of Gd-BOPTA in cholestatic fatty rat livers: Role of transport functions through membrane proteins[J]. Contrast Media Mol Imaging, 2013, 8(2): 147-156.
[10]	Manizate F, Hiotis SP, Labow D, et al. Liver functional reserve estimation:State of the art and relevance to local treatments[J]. Oncology, 2010, 78(11):131-134.
[11]	Tralhao JG, Hoti E, Oliveros B, et al. Study of perioperative liver function by dynamic monitoring of ICG-clearance[J]. Hepatogastroenterology, 2012, 59(116):1179-1183.
[12]	Granito A, Bolondi L. Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis[J]. Lancet Oncol, 2017, 18(2): e101-e112.
[13]	Sharma P. Value of liver function tests in cirrhosis[J]. J Clin Exp Hepatol, 2022, 12(3):948-964.
[14]	Demirtas CO, D'Alessio A, Rimassa L, et al. ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma[J]. JHEP Rep, 2021, 3(5):100347.
[15]	King J, Palmer DH, Johnson P, et al. Sorafenib for the treatment of advanced hepatocellular cancer-a UK audit[J]. Clin Oncol (R Coll Radiol), 2017, 29(4):256-262. doi: S0936-6555(16)30413-7 pmid: 27964898
[16]	Chow AM, Gao DS, Fan SJ, et al. Measurement of liver T₁ and T₂ relaxation times in an experimental mouse model of liver fibrosis[J]. J Magn Reson Imaging, 2012, 36(1):152-158.
[17]	Heye T, Yang SR, Bock M, et al. MR relaxometry of the liver: Significant elevation of T1 relaxation time in patients with liver cirrhosis[J]. Eur Radiol, 2012, 22(6):1224-1232.
[18]	Cassinotto C, Feldis M, Vergniol J, et al. MR relaxometry in chronic liver diseases: Comparison of T1 mapping, T 2 mapping, and diffusion-weighted imaging for assessing cirrhosis diagnosis and severity[J]. Eur J Radiol, 2015, 84(8):1459-1465.
[19]	Zhou X, Long L, Mo Z, et al. OATP1B3 expression in hepatocellular carcinoma correlates with intralesional Gd-EOB-DTPA uptake and signal intensity on Gd-EOB-DTPA-enhanced MRI[J]. Cancer Manag Res, 2021, 13:1169-1177. doi: 10.2147/CMAR.S292197 pmid: 33603462
[20]	Pastor C, Wissmeyer M, Millet P. Concentrations of Gd-BOPTA in cholestatic fatty rat livers: Role of transport functions through membrane proteins[J]. Contrast Media Mol Imaging, 2013, 8(2):147-156.

组别	例数	BMI (kg/m²)	性别[例(%)]		年龄 (岁)	乙型肝炎背景[例(%)]		AST[例(%)]		ALT[例(%)]		GGT[例(%)]
组别	例数	BMI (kg/m²)	男	女	年龄 (岁)	有	无	≤40 U/L	>40 U/L	≤50 U/L	>50 U/L	≤60 U/L	>60 U/L
A组	20	23.25±2.52	15(75.0)	5(25.0)	59.10±13.09	10(50.0)	10(50.0)	5(25.0)	15(75.0)	10(50.0)	10(50.0)	6(30.0)	14(70.0)
B组	22	25.54±4.26	19(86.4)	3(13.6)	58.23±12.01	14(63.6)	8(36.4)	5(22.7)	17(77.3)	13(59.1)	9(40.9)	5(22.7)	17(77.3)
C组	15	24.98±4.27	11(73.3)	4(26.7)	64.67±11.08	9(60.0)	6(40.0)	5(33.3)	10(66.7)	8(53.3)	7(46.7)	3(20.0)	12(80.0)
统计值		t=2.063	χ²=1.200		t=1.379	χ²=0.836		χ²=0.545		χ²=0.358		χ²=0.528
P值		0.137	0.549		0.260	0.658		0.762		0.836		0.768

组别	例数	BMI (kg/m²)	性别[例(%)]		年龄 (岁)	乙型肝炎背景[例(%)]		AST[例(%)]		ALT[例(%)]		GGT[例(%)]
组别	例数	BMI (kg/m²)	男	女	年龄 (岁)	有	无	≤40 U/L	>40 U/L	≤50 U/L	>50 U/L	≤60 U/L	>60 U/L
A组	20	23.25±2.52	15(75.0)	5(25.0)	59.10±13.09	10(50.0)	10(50.0)	5(25.0)	15(75.0)	10(50.0)	10(50.0)	6(30.0)	14(70.0)
B组	22	25.54±4.26	19(86.4)	3(13.6)	58.23±12.01	14(63.6)	8(36.4)	5(22.7)	17(77.3)	13(59.1)	9(40.9)	5(22.7)	17(77.3)
C组	15	24.98±4.27	11(73.3)	4(26.7)	64.67±11.08	9(60.0)	6(40.0)	5(33.3)	10(66.7)	8(53.3)	7(46.7)	3(20.0)	12(80.0)
统计值		t=2.063	χ²=1.200		t=1.379	χ²=0.836		χ²=0.545		χ²=0.358		χ²=0.528
P值		0.137	0.549		0.260	0.658		0.762		0.836		0.768

观察者	SI_T2(×10²)	SI_肝胆期(×10²)	SI_平扫(×10²)
观察者1	1.02±0.29	2.95±0.57	1.80±0.37
观察者2	1.19±0.30	3.23±0.53	1.97±0.34
ICC值	0.830	0.920	0.900

观察者	SI_T2(×10²)	SI_肝胆期(×10²)	SI_平扫(×10²)
观察者1	1.02±0.29	2.95±0.57	1.80±0.37
观察者2	1.19±0.30	3.23±0.53	1.97±0.34
ICC值	0.830	0.920	0.900

组别	例数	SI_T2 (×10²)	SI_平扫 (×10²)	SI_肝胆期 (×10²)	RE
A组	20	1.05±0.23	1.94±0.35	3.49±0.56	0.82±0.27
B组	22	1.18±0.24	2.03±0.27	3.16±0.48^*	0.57±0.24^*
C组	15	1.39±0.36^*#	1.97±0.34	2.99±0.53^*#	0.57±0.21^*#
F值		6.680	0.490	4.730	6.960
P值		0.003	0.616	0.013	0.002

Value of T₂WI signal intensity and gadobemeglumine enhanced MRI hepatobiliary phase parameters in evaluating liver function of cirrhosis patients

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 8

References 20

Related Articles 15

Recommended Articles

Metrics

Comments

参数	AUC	95%CI		界值	敏感度	特异度
参数	AUC	下限	上限	界值	敏感度	特异度
SI_T2(×10²)	0.715	0.580	0.827	1.07	0.810	0.600
SI_肝胆期(×10²)	0.707	0.571	0.820	3.25	0.676	0.700
RE	0.757	0.625	0.861	0.69	0.811	0.700
SI_T2+SI_肝胆期+RE	0.846	0.726	0.928	0.64	0.784	0.800

参数	AUC差值	Z值	P值
SI_T2与SI_肝胆期	0.008	0.071	0.944
SI_T2与RE	0.042	0.435	0.664
SI_T2与SI_T2+SI_肝胆期+RE	0.131	1.848	0.065
SI_肝胆期与RE	0.050	0.625	0.532
SI_肝胆期与SI_T2+SI_肝胆期+RE	0.139	2.313	0.021
RE与SI_T2+SI_肝胆期+RE	0.089	1.852	0.064

[1]	Su Rui, Wang Cunkai, Wang Dingxin, Cai Conghui, Zhang Jian, Hou Hongtao, Bai Yun. Efficacy and safety of anticoagulant therapy in patients with cirrhosis: A meta-analysis [J]. Clinical Focus, 2025, 40(4): 293-303.
[2]	Qian Chenying, Yan Wenjun, Huang Yan, Zhao Zhi. Analysis of risk factors for multidrug-resistant bacterial infection in patients with decompensated cirrhosis [J]. Clinical Focus, 2025, 40(2): 143-146.
[3]	Zhang Shasha, Zhao Yingchun, Zhou Hongxia. Effect of low-level viremia on the incidence of hepatocellular carcinomas in patients with hepatitis B cirrhosis treated with entecavir [J]. Clinical Focus, 2024, 39(11): 980-983.
[4]	Zheng Zilei, Yang Yanjiang, Li Haiying. Protection and effect of dexmedetomidine on liver and kidney function of incarcerated inguinal hernia caused intestinal ischemia and reperfusion injury in the elderly surgical patients [J]. Clinical Focus, 2021, 36(8): 735-738.
[5]	Huo Xiaoxia, Niu Weiwei, Han Xu, Zhang Xiaolan. Effects of dense ligation on liver function and hemodynamics in patients with esophageal variceal bleeding [J]. Clinical Focus, 2021, 36(3): 238-241.
[6]	Cheng Mingrong, Dai Dejian. Efficacy of Zhenqi Fuzheng Capsule combined with ursodeoxycholic acid on primary biliary cholangitis and its impact on thyroid function [J]. Clinical Focus, 2020, 35(3): 260-263.
[7]	Wang Yankun1， Ma Junji2, Zhang Ming2. Role of cytokeratin 7 in pathological diagnosis of liver cirrhosis [J]. Clinical Focus, 2019, 34(2): 124-127.
[8]	Huang Guangming, Gu Dahui, Hao Yaqin, He Zhijun. Effect of nutritional status on clinical outcomes in elderly patients with hepatic cirrhosis [J]. Clinical Focus, 2019, 34(2): 128-131.
[9]	Jin Yan, Ge Zhihua, Sun Yuanyuan, Xu Shuyan, Shao Jianguo. Clinical study of AIMS65 score for risk assessment of esophagealgastric variceal bleeding in liver cirrhosis [J]. Clinical Focus, 2018, 33(6): 498-501.
[10]	Zhao Wen， Zhang Siyu， Lu Yu， Zhao Suxian， Wang Rongqi， Nan Yuemin. FibroTouch combined with FIB-4， APRI and GPRI in diagnosis of liver fibrosis [J]. Clinical Focus, 2018, 33(2): 140-144.
[11]	Yin Kaige, Jin Xiaoxu, Feng Zhijie. Endoscopic treatment of esophagogastric varices in cirrhosis [J]. Clinical Focus, 2018, 33(11): 929-932.
[12]	Cheng Ran, Xu Xiaoyuan. Diagnosis and therapy of ascites in liver cirrhosis [J]. Clinical Focus, 2018, 33(11): 921-924.
[13]	Yang Xincheng, Jin Xiaoxu, Yao Jinfeng. Research advances of portal vein thrombosis in liver cirrhosis [J]. Clinical Focus, 2018, 33(11): 947-949，955.
[14]	Xu Manman1, Cheng Kailiang2, Qiu Qian3, Zhao Xinyu2, Duan Zhongping1, Wang Li2, Chen Yu1. Factors associated with adherence to antiviral therapy in patients with HBV-related cirrhosis [J]. Clinical Focus, 2018, 33(11): 950-955.
[15]	Kong Ming， Shi Hongbo， Bai Li， Yao Jia， Chen Yu， Duan Zhongping. Characteristics of plasma amino acids in patients with HBVrelated chronic hepatitis， cirrhosis and acute on chronic liver failure [J]. Clinical Focus, 2016, 31(7): 732-735,740.